135394-17-1

Basic information

• Product Name: 2-chloro-9-methyl-N⁶-phenyladenine
• Synonyms: 2-chloro-9-methyl-N⁶-phenyladenine
• CAS NO: 135394-17-1
• Molecular Weight: 259.698
• Mol File: 135394-17-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-chloro-9-methyl-N⁶-phenyladenine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-9-methyl-N⁶-phenyladenine(135394-17-1)
• EPA Substance Registry System: 2-chloro-9-methyl-N⁶-phenyladenine(135394-17-1)

Safety Data

• Hazardous Substances Data: 135394-17-1(Hazardous Substances Data)

Upstream product

• 2382-10-7 2,6-dichloro-9-methyl-9H-purine 
• 62-53-3 aniline 
• 5451-40-1 2,6 dichloropurine 
• 185408-97-3 2-chloro-N-phenyl-9H-purin-6-amine 
• 74-88-4 methyl iodide 

Downstream Products

• 1402821-31-1 (R)-2-(9-methyl-6-(phenylamino)-9H-purin-2-ylamino)butan-1-ol 

Relevant articles and documents

Pyrimido five-membered heterocyclic compound and application as mutant IDH2 inhibitor

The invention relates to a pyrimido five-membered heterocyclic compound and an application of the pyrimido five-membered heterocyclic compound as a mutant IDH2 inhibitor, and specifically discloses apyrimido five-membered heterocyclic compound capable of being used as a mutant IDH2 inhibitor, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The invention also relates to a pharmaceutical composition containing the compound, and application of the pharmaceutical composition in preparation of drugs for preventing and/or treating mutantIDH2 mediated diseases.

Synthesis and biological evaluation of a selective N- and P/Q-Type calcium channel agonist

The acute effect of the potent cyclin-dependent kinase (cdk) inhibitor (R)-roscovitine on Ca2+ channels inspired the development of structural analogues as a potential treatment for motor nerve terminal dysfunction. On the basis of a versatile chlorinated purine scaffold, we have synthesized ca. 20 derivatives and characterized their N-type Ca2+ channel agonist action. Agents that showed strong agonist effects were also characterized in a kinase panel for their off-target effects. Among several novel compounds with diminished cdk activity, we identified a new lead structure with a 4-fold improved N-type Ca2+ channel agonist effect and a 22-fold decreased cdk2 activity as compared to (R)-roscovitine. This compound was selective for agonist activity on N- and P/Q-type over L-type calcium channels.

N6,9-Disubstituted Adenines: Potent, Selective Antagonists at the A1 Adenosine Receptor

N6-Substituted 9-methyladenines are potent antagonists of the activation of A1 adenosine receptors.The present study assessed the effect of N6 and N-9-substituents on the binding of adenines to the A1 and A2 receptors, respectively, of rat brain cortex and striatum and also on the antagonism of the A2 receptor mediated stimulation of the adenylate cyclase of PC12 cells by N-ethyladenosine-5'-uronamide.The potency ranking of 9-substituted adenines varied directly with the hydrophobicity of the substituent: cyclopentyl > phenyl > tetrahydrofuryl > ethyl > methyl > 2-hydroxyethyl.The 9-substituted adenines showed little selectivity for either receptor and the R enantiomer of N6-(1-phenyl-2-propyl)-9-methyladenine was only 4-fold more potent than the S enantiomer at the A1 receptor.An N6-cyclopentyl substituent increased potency at the A1 receptor and decreased potency at the A2 receptor, resulting in selectivity for the A1 receptor of up to 39-fold.The N6-cyclopentyl group completely overshadowed the effect of the hydrophobicity of the 9-substituent.A 2-chloro substituent did not alter the potency of an N6-substituted 9-methyladenine.